Rituximab IPR Updates

Today, Pfizer filed a notice that it will not participate in the appeal of the final written decision of IPR2017-01168, which found all claims of U.S. Patent No. 8,821,873 unpatentable. The ‘873 patent is directed to a method of treating lymphoma with anti-CD20 antibodies.

Yesterday, Pfizer and Biogen filed a joint motion to terminate IPR2018-00285 regarding U.S. Patent No. 8,329,172 “due to the settlement between the parties.”  IPR2018-00285 was instituted in July 2018, and the ‘172 patent is directed to methods for treating low grade B-cell non-Hodgkin’s lymphoma. The parties also filed a joint motion to treat the settlement agreement as confidential.

Download PDF